drugset / Trial / NCT04523688
Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumour Homogenate in Glioblastoma
Phase 2
Recruiting
28 enrolled
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
NaSingle-groupOpen-labelTreatment
Summary
Single arm, monocentric trial to assess the safety and the progression-free survival related to the combined treatment of dendritic cell vaccine loaded with autologous tumor homogenate and temozolomide in patients operated for glioblastoma and then treated with standard radiochemotherapy (according to Stupp regimen).
Timeline
- Start
- 2021-03-25
- Primary completion
- 2025-07
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous Dendritic Cells (DC) vaccine | Unknown | 1e+07 cells | Other |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | Oral |